ClinicalTrials.gg
CompletedNCT00751790Updated Jul 25, 2014Results posted

Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer

A Phase 3 interventional study of triptorelin embonate (INN) in Prostatic Neoplasm, sponsored by Debiopharm International SA. Completed at 1 site in South Africa. Open to male participants. Per ClinicalTrials.gov, last updated 2014-07-25.

Sponsored by Debiopharm International SA (part of Debiopharm) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.

Enrollment
14th of 28
120 · median 120
Started
2006
with 1 other
Phase 3
12 of 28
2 open now
Registered
6th of 28
by date
Lead sponsor
2 of 28
Debiopharm International SA

Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 14th largest by enrollment, is one of 2 that started in 2006, is one of 12 in phase 3, and was the 6th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About triptorelin

triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing triptorelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Efficacy and safety of a triptorelin 6-month formulation in patients with advanced prostate cancer. It was assumed that during the study treatment >90% of the patients would achieve and maintain castrate levels of serum testosterone.

Read the detailed description

Efficacy of triptorelin treatment on gonadotropin (LH) stimulation from hypophysis, as well as on the PSA (prostate specific antigen) levels and safety laboratory parameters. The triptorelin pharmacokinetics and testosterone pharmacodynamics were assessed in a subset of 15 patients.

03

Conditions studied

  • Prostatic Neoplasm

Browse trials for

Keywords

  • triptorelin, 6-month formulation, advanced prostate cancer
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically proven prostate cancer.
  • The prostate cancer should be staged T3-4NxMx or TxN1-3Mx or TxNxM1 according to the TNM classification or the patient should have rising PSA after failed local therapy and be candidate for androgen deprivation therapy.
  • Serum testosterone levels >5 nmol/L.
  • performance index >40.
  • Expected survival > 18 months.
  • Absence of another , other than local dermatological, for the previous 5 years.
  • Signed before entry into the study.

Exclusion criteria

Exclusion Criteria:

  • Prior hormonal treatment for prostate cancer within 6 months prior to study start.
  • Use of finasteride (Proscar®) or dutasteride (Avodart®/Avolve®) within 2 months prior to study start.
  • Presence of another neoplastic lesion or .
  • Prior hypophysectomy or adrenalectomy.
  • Known or suspicion of vertebral with risk of spinal compression.
  • Severe kidney or liver failure (creatinine > 2 times the upper normal limit, ASAT and ALAT >3 times the upper normal limit).
  • Any concomitant disorder or resulting therapy that is likely to interfere with patient compliance or with the study in the opinion of the Investigator.
  • Participation in another study with an experimental drug within 3 months before study start or within 5 drug half-lives of the drug (whichever is the longer).
  • Known to any of the test materials or related compounds.
  • Known active use of recreational drug or alcohol dependence in the opinion of the Investigator.
  • Any current use or use within 6 months prior to treatment start of medications which are known to affect the metabolism and/or secretion of androgenic hormones: ketoconazole, aminoglutethimide, oestrogens, and progesterone.
  • Use of systemic or inhaled (topical application permitted).
  • Use of anticoagulants: heparin and coumarine derivatives (acetylsalicylic acid permitted).
  • Inability to give or to comply fully with the protocol.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Triptorelin

    Drug: triptorelin embonate (INN)

Interventions

06

What researchers measure

Primary outcomes

  1. Achievement of Castration and Maintenance of Castration

    Percentage of patients achieving castrate testosterone levels (≤1.735 nmol/L) by Day 29 (28 days after study drug injection) and percentage of patients maintaining castrate testosterone levels from Month 2 to end of Month 12 (Week 48).

    Time frame: at Day 29

Secondary outcomes

  1. LH Increase

    % of patients showing ≤1.0 IU/L increase in s-LH from 0 to 2 h after 1st \& 2nd injection.% changes in PSA throughout treatment.% of 60 pts with s-testosterone levels \>1.735 nmol/L after 2nd injection.Testosterone PD and triptorelin PK metrics in 15 pts

    Time frame: day 1 and day 169

07

Results

Posted Jun 13, 2012

Participant flow

Participant flow — Overall Study
MilestoneTriptorelin
Started120
Completed115
Not completed5
Withdrew: Lost to follow-up1
Withdrew: Death3
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryAchievement of Castration and Maintenance of Castration

Percentage of patients achieving castrate testosterone levels (≤1.735 nmol/L) by Day 29 (28 days after study drug injection) and percentage of patients maintaining castrate testosterone levels from Month 2 to end of Month 12 (Week 48).

Time frame:
at Day 29
Reported as:
Number · percentage of enrolled patients
Achievement of Castration and Maintenance of Castration
percentage of enrolled patientsTriptorelin
Achievement of Castration and Maintenance of Castration97.5
SecondaryLH Increase

% of patients showing ≤1.0 IU/L increase in s-LH from 0 to 2 h after 1st \& 2nd injection.% changes in PSA throughout treatment.% of 60 pts with s-testosterone levels \>1.735 nmol/L after 2nd injection.Testosterone PD and triptorelin PK metrics in 15 pts

Time frame:
day 1 and day 169
Reported as:
Number · patient

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triptorelin—17/120 (14.2%)115/120 (95.8%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventTriptorelin
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/120
Acute myocardial infarctionCardiac disorders1/120
Angina pectorisCardiac disorders1/120
Atrial flutterCardiac disorders1/120
Myocardial infarctionCardiac disorders1/120
Diabetes mellitusEndocrine disorders1/120
PneumoniaInfections and infestations1/120
skin lacerationInjury, poisoning and procedural complications1/120
Soft tissue injuryInjury, poisoning and procedural complications1/120
Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/120
Most frequent other events
Showing 10 of 14
Most frequent other events
EventTriptorelin
Hot flushVascular disorders87/120
InfluenzaInfections and infestations19/120
HypertensionVascular disorders17/120
Back painMusculoskeletal and connective tissue disorders13/120
Erectile dysfunctionReproductive system and breast disorders12/120
Urinary tract infectionRenal and urinary disorders11/120
ArthralgiaMusculoskeletal and connective tissue disorders9/120
Pain in extremityMusculoskeletal and connective tissue disorders9/120
HeadacheNervous system disorders9/120
Testicular atrophyReproductive system and breast disorders9/120

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Triptorelin
<=18 years0
Between 18 and 65 years0
>=65 years120
Age, Continuous
Age, Continuous(years)Triptorelin
Mean71.11 ± 8.46
Sex: Female, Male
Sex: Female, Male(Participants)Triptorelin
Female0
Male120
Region of Enrollment
Region of Enrollment(participants)Triptorelin
South Africa120
08

Study locations

1 site
  • Quintiles South Africa
    Lyttelton Manor, Centurion 0157, South Africa
09

References and documents

Publications

  • Lundstrom EA, Rencken RK, van Wyk JH, Coetzee LJ, Bahlmann JC, Reif S, Strasheim EA, Bigalke MC, Pontin AR, Goedhals L, Steyn DG, Heyns CF, Aldera LA, Mackenzie TM, Purcea D, Grosgurin PY, Porchet HC. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig. 2009;29(12):757-65. doi: 10.2165/11319690-000000000-00000. PubMed 19888782 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Aug 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2008
First posted
Sep 12, 2008
Start
Jul 2006
Primary completionActual
Aug 2007
CompletionActual
Aug 2007
Results first posted
Jun 13, 2012
Last update
Jul 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00751790
Responsible party
Sponsor
First posted
Sep 12, 2008
Start date
Jul 2006
Primary completion
Aug 2007
Completion
Aug 2007
Results posted
Jun 13, 2012
Last update
Jul 25, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion